Table of Content

Introduction
Global Markets Direct Report Coverage
Metachromatic Leukodystrophy (MLD) - Overview
Metachromatic Leukodystrophy (MLD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Metachromatic Leukodystrophy (MLD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metachromatic Leukodystrophy (MLD) - Companies Involved in Therapeutics Development
Affinia Therapeutics
ArmaGen Inc
Deli Therapeutics Inc
Homology Medicines Inc
Orchard Therapeutics Plc
Passage Bio Inc
Recursion Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Metachromatic Leukodystrophy (MLD) - Drug Profiles
AGT-183 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atidarsagene autotemcel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Replace Arylsulfatase A (ARSA) for Metachromatic Leukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Metachromatic Leukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMI-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBML-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-611 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metachromatic Leukodystrophy (MLD) - Dormant Projects
Metachromatic Leukodystrophy (MLD) - Discontinued Products
Metachromatic Leukodystrophy (MLD) - Product Development Milestones
Featured News & Press Releases
May 11, 2021: Passage Bio announces pre-clinical data presentation at Annual ASGCT Meeting
Feb 13, 2020: Homology Medicines presents new data characterizing AAVHSCs as potential gene therapies for nervous system disorders
Oct 21, 2019: Homology Medicines presents data from investigatiol MLD gene therapy program HMI-202 at the American Society of Human Genetics (ASHG) 2019 Meeting
Nov 07, 2018: Homology Medicines presents data on platform’s ability to target the central and peripheral nervous system and therapeutic potential in the rare disease Metachromatic Leukodystrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Metachromatic Leukodystrophy (MLD), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Metachromatic Leukodystrophy (MLD), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Metachromatic Leukodystrophy (MLD) - Pipeline by Affinia Therapeutics, 2021
Metachromatic Leukodystrophy (MLD) - Pipeline by ArmaGen Inc, 2021
Metachromatic Leukodystrophy (MLD) - Pipeline by Denali Therapeutics Inc, 2021
Metachromatic Leukodystrophy (MLD) - Pipeline by Homology Medicines Inc, 2021
Metachromatic Leukodystrophy (MLD) - Pipeline by Orchard Therapeutics Plc, 2021
Metachromatic Leukodystrophy (MLD) - Pipeline by Passage Bio Inc, 2021
Metachromatic Leukodystrophy (MLD) - Pipeline by Recursion Pharmaceuticals Inc, 2021
Metachromatic Leukodystrophy (MLD) - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Metachromatic Leukodystrophy (MLD) - Dormant Projects, 2021
Metachromatic Leukodystrophy (MLD) - Discontinued Products, 2021